Achieve Life Sciences, Inc. (QUIT)
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
- Ticker
- QUIT
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $649.88M
- 52-week range
- $2.62 - $8.64
Valuation
- Share price
- $5.92 (close of Nov 18, 2026)
- P/E (TTM)
- -4.32x
- Price to book
- 3.60x
- Price to free cash flow
- -14.74x
- Enterprise value
- $462.43M
- Book value per share
- $1.65
Price performance
| Period | Change |
|---|---|
| 1 day | -3.27% |
| 5 days | -8.22% |
| 1 month | -7.21% |
| 3 months | -21.28% |
| 6 months | +24.11% |
| Year to date | +19.11% |
| 1 year | +36.72% |
| 3 years | +11.70% |
| 5 years | -21.17% |
| 10 years | -99.45% |
| All time | -100.00% |
Profitability and growth
- Return on equity
- -253.96%
- Return on invested capital
- -147.59%*
- Return on assets
- -130.77%
- Return on capital employed
- -164.57%*
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -6.79%
- Current ratio
- 10.49x
- Net debt to EBITDA
- 1.70x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- EBITDA
- -$53.60M
- Net income
- -$54.65M
- Earnings per share
- $-1.25
- Interest expense
- $819.00K
- Shares outstanding
- 43.59M
Income statement by year
| Period end | Net income | EPS |
|---|---|---|
| 2025-12-31 | -$54.65M | -$1.25 |
| 2024-12-31 | -$39.83M | -$1.24 |
| 2023-12-31 | -$29.82M | -$1.50 |
| 2022-12-31 | -$42.35M | -$4.00 |
| 2021-12-31 | -$33.15M | -$4.08 |
| 2020-12-31 | -$14.73M | -$5.42 |
| 2019-12-31 | -$16.39M | -$39.76 |
| 2018-12-31 | -$12.69M | -$72.29 |
| 2017-12-31 | -$10.58M | -$441.40 |
| 2016-12-31 | -$1.23M | -$11,625.00 |
Margins and returns by year
| Period end | Return on equity | Return on capital |
|---|---|---|
| 2025-12-31 | -253.96% | -147.59%* |
| 2024-12-31 | -190.57% | -122.00%* |
| 2023-12-31 | - | -176.42%* |
| 2022-12-31 | - | -165.55%* |
| 2021-12-31 | -118.22% | -77.03%* |
| 2020-12-31 | -39.51% | -39.33%* |
| 2019-12-31 | -90.83% | -89.05%* |
| 2018-12-31 | -80.29% | -80.17%* |
| 2017-12-31 | -66.97% | -86.28%* |
| 2016-12-31 | -202.30% | -284.92%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $36.40M | $11.19M |
| 2024-12-31 | $34.40M | $9.84M |
| 2023-12-31 | $15.55M | - |
| 2022-12-31 | $24.77M | - |
| 2021-12-31 | $43.02M | $14.92M |
| 2020-12-31 | $35.85M | - |
| 2019-12-31 | $16.70M | - |
| 2018-12-31 | $14.60M | - |
| 2017-12-31 | $5.28M | - |
| 2016-12-31 | $25.50M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | -$49.47M | $8.76M |
| 2024-12-31 | -$29.77M | $5.33M |
| 2023-12-31 | -$24.50M | $3.44M |
| 2022-12-31 | -$37.57M | $3.27M |
| 2021-12-31 | -$29.44M | $2.19M |
| 2020-12-31 | -$13.49M | $1.29M |
| 2019-12-31 | -$15.27M | $1.20M |
| 2018-12-31 | -$10.67M | $854.00K |
| 2017-12-31 | -$9.11M | $348.00K |
| 2016-12-31 | -$248.00K | $1.65M |
Investor relations
Next earnings report
- Next confirmed report
- Nov 19, 2026
- Consensus EPS estimate
- $-0.19
Filings and sources
- Company website
- achievelifesciences.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades